Petosemtamab Plus Chemotherapy for Left-sided Colorectal Cancer

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

Recruiting Phase 3 Interventional Study
Left-sided Colorectal Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
960 (estimated)
Sponsor
Genmab · Industry
Who this trial is looking for

This trial is looking for people with left-sided colorectal cancer that cannot be removed with surgery. Participants will receive treatment with either petosemtamab plus chemotherapy or standard care cetuximab plus chemotherapy while undergoing regular check-ups.

Are You a Good Fit for This Trial?
Rules you out Microsatellite instability-highDeficient mismatch repairNon-colorectal adenocarcinomatous disease

You may be able to join if

  • I have been diagnosed with left-sided colorectal cancer.
  • My cancer cannot be surgically removed or has spread.
  • I have not received any prior treatment for my cancer.
  • I have test results showing my cancer is KRAS and NRAS wild type.

You may not be able to join if

  • I have a BRAF mutation.
  • I have been treated with agents that target EGFR.
  • I have known complete DPD deficiency.
  • I am homozygous for the UGT1A1*28 or *6 alleles.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or standard-of-care cetuximab + doctor's choice …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Key Inclusion Criteria: * Histologically or cytologically confirmed left-sided colorectal adenocarcinoma that is unresectable or metastatic. * Must have documented KRAS and NRAS wild type (wt) colorectal cancer (CRC), as determined by medical record of results from local testing or as assessed by c…
Contacts

Genmab Trial Information

+4570202728

clinicaltrials@genmab.com

CONTACT